To hear about similar clinical trials, please enter your email below

Trial Title: Erdafitinib Monotherapy or in Combination With Cetrelimab in Muscle-invasive Bladder Cancer Patients With Fibroblast Growth Factor Receptor (FGFR ) Gene Alterations

NCT ID: NCT06511648

Condition: Muscle-invasive Bladder Cancer

Conditions: Official terms:
Urinary Bladder Neoplasms

Conditions: Keywords:
Urothelial carcinoma

Study type: Interventional

Study phase: Phase 2

Overall status: Recruiting

Study design:

Allocation: Non-Randomized

Intervention model: Parallel Assignment

Primary purpose: Treatment

Masking: None (Open Label)

Intervention:

Intervention type: Drug
Intervention name: Erdafitinib monotherapy
Description: Patients will receive treatment with erdafitinib alone (cohort 1)
Arm group label: Erdafitinib (ERDA) monotherapy

Intervention type: Drug
Intervention name: Cetrelimab and Erdafitinib combination
Description: Patients will receive treatment neoadjuvant with erdafitinib plus cetrelimab intravenously (IV).(cohort 2)
Arm group label: Erdafitinib (ERDA) and Cetrelimab (CET) combination

Summary: Erdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express Fibroblast Growth Factor Receptor (FGFR )gene alterations and are ineligible for or refuse cisplatin based neoadjuvant chemotherapy.

Detailed description: The aim of the study is to assess the antitumor activity measured as ypT0 rate, defined as no evidence of residual disease based on pathological review of the surgical specimen (pCR) and tumour downstaging (

Criteria for eligibility:
Criteria:
Inclusion Criteria: 1. Written informed consent stating that he or she understands the purpose of the study and the procedures involved and agrees to participate in the study. 2. Histologically confirmed diagnosis of MIBC (Stage T2-4a N0/N1 M0) obtained via a diagnostic or maximal Transurethral Resection of Bladder Tumor (TURBT) performed no later than 3 months prior to start the screening visit. 3. Pure or predominant (≥50%) urotelial Cancer (UC) histology as determined at the local site. 4. Age ≥ 18 years. 5. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 6. Decline or ineligible ("unfit") for cisplatin-based chemotherapy 7. Presence of a selected FGFR alteration on analysis of tumour biopsy 8. Adequate organ function 9. No other malignancy 10. Willingness to avoid pregnancy or fathering children Exclusion Criteria: 1. Clinical evidence of N2-N3 tumours or metastatic bladder cancer. 2. Has tumour with any neuroendocrine or small cell component. 3. Patients who are not considered fit for cystectomy or reject cystectomy. 4. Prior FGFR-targeted or an immune checkpoint inhibitor (antiPD1/PDL1 )systemic therapy. 5. Prior systemic therapy, radiation therapy, or surgery for bladder cancer

Gender: All

Minimum age: 18 Years

Maximum age: N/A

Healthy volunteers: No

Locations:

Facility:
Name: CLCC Jean Perrin

Address:
City: Clermont-Ferrand
Zip: 63011
Country: France

Status: Not yet recruiting

Contact:
Last name: Hakim Mahammedi, MD and PhD
Email: hakim.mahammedi@clermont.unicancer.fr

Facility:
Name: CLCC Léon Bérard

Address:
City: Lyon
Zip: 69008
Country: France

Status: Recruiting

Contact:
Last name: Aude Flechon, MD, PhD
Email: aude.flechon@lyon.unicancer.fr

Facility:
Name: Institut Mutualiste Montsouris

Address:
City: Paris
Zip: 75014
Country: France

Status: Not yet recruiting

Contact:
Last name: Mostefa Bennamoun, MD, PhD
Email: Mostefa.Bennamoun@imm.fr

Facility:
Name: IUCT

Address:
City: Toulouse
Zip: 31059
Country: France

Status: Recruiting

Contact:
Last name: Damien Poussel, MD, PhD
Email: pouessel.damien@iuct-oncopole.fr

Facility:
Name: Institut Gustave Roussy

Address:
City: Villejuif
Zip: 94805
Country: France

Status: Recruiting

Contact:
Last name: Yohann Loriot, MD, PhD
Email: Yohann.LORIOT@gustaveroussy.fr

Facility:
Name: IRCCS San Raffaele Hospital and Scientific Institute

Address:
City: Milan
Zip: 20132
Country: Italy

Status: Recruiting

Contact:
Last name: Andrea Necchi, MD, PhD
Email: necchi.andrea@hsr.it

Facility:
Name: Ospedale Molinette

Address:
City: Turin
Zip: 10126
Country: Italy

Status: Not yet recruiting

Contact:
Last name: Paolo Gontero, MD, PhD
Email: paolo.gontero@unito.it

Facility:
Name: A.O. Ordine Mauriziano, Ospedale Umberto I

Address:
City: Turi
Zip: 10128
Country: Italy

Status: Recruiting

Contact:
Last name: Giorgio Valabrega, MD, PhD
Email: giorgio.valabrega@unito.it

Facility:
Name: Hospital Clínic De Barcelona

Address:
City: Barcelona
Zip: 08036
Country: Spain

Status: Recruiting

Contact:
Last name: Oscar Reig, MD, PhD.

Contact backup:
Last name: OREIG@clinic.cat

Facility:
Name: Hospital De Sabadell (Parc Taulí)

Address:
City: Barcelona
Zip: 08208
Country: Spain

Status: Recruiting

Contact:
Last name: Teresa Bonfill, MD, PhD.
Email: TBonfill@tauli.cat

Facility:
Name: Complexo Hospitalario Universitario A Coruña

Address:
City: Coruña
Zip: 15006
Country: Spain

Status: Recruiting

Contact:
Last name: Aurea Molina, MD, PhD

Contact backup:
Email: aurea.molina.diaz@sergas.es

Facility:
Name: Hospital Universitario Lucus Augusti

Address:
City: Lugo
Zip: 27003
Country: Spain

Status: Recruiting

Contact:
Last name: Sergio Vázque, MD, PhD

Contact backup:
Email: sergio.vazquez.estevez@sergas.es

Facility:
Name: Hospital Universitario 12 de Octubre

Address:
City: Madrid
Zip: 28041
Country: Spain

Status: Recruiting

Contact:
Last name: Guillermo De Velasco, MD, PhD
Email: guillermoantonio.velasco@salud.madrid.org

Facility:
Name: Fundación Instituto Valenciano De Oncología

Address:
City: Valencia
Zip: 46009
Country: Spain

Status: Recruiting

Contact:
Last name: Maria José Juan, MD, Phd
Email: mjuanfi81@hotmail.com

Facility:
Name: University Hospitals of Morecambe Bay NHS Foundation Trust

Address:
City: Lancaster
Zip: LA1 4RP
Country: United Kingdom

Status: Not yet recruiting

Contact:
Last name: Alison Birtle, MD, PhD
Email: Alison.birtle@lthtr.nhs.uk

Facility:
Name: The Royal Marsden NHS Foundation Trust

Address:
City: London
Zip: SW3 6JJ
Country: United Kingdom

Status: Not yet recruiting

Contact:
Last name: Vincent Khoo, MD, PhD
Email: VincentPA.Khoo@rmh.nhs.uk

Facility:
Name: Barts Health NHS Trust

Address:
City: London
Zip: W6 8JA
Country: United Kingdom

Status: Not yet recruiting

Contact:
Last name: Tomas Powles, MD, PhD
Email: thomas.powles1@nhs.net

Facility:
Name: Charing Cross Hospital

Address:
City: London
Country: United Kingdom

Status: Not yet recruiting

Contact:
Last name: Naveed Sarwar, MD, PhD
Email: naveed.sarwar1@nhs.net

Facility:
Name: Sheffield Teaching Hospitals NHS Foundation Trust

Address:
City: Sheffield
Zip: S10 2SJ
Country: United Kingdom

Status: Not yet recruiting

Contact:
Last name: Syed Hussain, MD, PhD
Email: syed.hussain@sheffield.ac.uk

Start date: March 7, 2023

Completion date: March 2029

Lead sponsor:
Agency: Spanish Oncology Genito-Urinary Group
Agency class: Other

Collaborator:
Agency: Janssen-Cilag Ltd.
Agency class: Industry

Collaborator:
Agency: Pivotal S.L.
Agency class: Industry

Source: Spanish Oncology Genito-Urinary Group

Record processing date: ClinicalTrials.gov processed this data on November 12, 2024

Source: ClinicalTrials.gov page: https://clinicaltrials.gov/ct2/show/NCT06511648

Login to your account

Did you forget your password?